RETRACTED: Use of biologics in patients with psoriasis – A retrospective analysis based on real‐world data
Skin Research and Technology · 2024-01 · 30 (1)
DOI: 10.1111/srt.13550 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Skin Research and Technology, online erschienen am 04.01.2024. Verfasst von Jing Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Biological Products, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To summarize and analysis the application of biologic agents in patients with psoriasis in the real world.
Methods
Relying on collected data from June 2020 to September 2021 in the database of China Psoriasis Standardized Diagnosis and Treatment Center, 2529 cases of psoriasis patients treated with biologic agents in 188 different tertiary hospitals across China were retrospective analyzed. The collected information mainly includes demographic data (age, gender, psoriasis history), curative effectiveness of used biologics drug withdrawal and its reason. According to the collected information, condition of the usage for each category of biologics and influencing factor of biologics replacement were analyzed.
Result
A total of 2529 patients were analyzed, which included 1626 male (64.29%) and 903 female (35.71%) with an average age of 42.12 ± 14.70 (17 ∼ 85) years old; 2336 (92.37%) patients were aged from 19 to 60 years old. Within these patients, 2362 of them (93.40%) had a psoriasis area and severity index (PASI) score, and 1776 of these patients had moderate to severe cases (75.19%). According to the patient's self‐evaluation of the past efficacy of biological agents, secukinumab was chosen by the most people to have the highest efficacy (1140 cases, 93.60%). The main reason for the withdrawal of secukinumab is that the disease is already well controlled at the time of withdrawal (67 cases, 38.95%); for TNF‐ α inhibitor is the poor curative effect; for ustekinumab and ixekizumab were the non‐affordable price.
Conclusions
In the current biotherapy of psoriasis in China, the efficacy of secukinumab is thought by most people to be the highest. Secukinumab is the first choice when the needs of changing biologics appear.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Venereology, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
- National Clinical Research Center for Dermotologic Diseases and Immunologic Diseases, Beijing, China.
- Department of Clinical Epidemiology Research Center, Beijing Jishuitan Hospital, Capital Medical University, Beijing, China.
Zitieren
APA
Pan, J., Chang, X., Wang, L., Miao, G., Jin, Q., Guo, N., Zhang, J., Lv, Y., & Wang, L. (2024). RETRACTED: Use of biologics in patients with psoriasis – A retrospective analysis based on real‐world data. Skin Research and Technology, 30(1). https://doi.org/10.1111/srt.13550
Vancouver
Pan J, Chang X, Wang L, Miao G, Jin Q, Guo N, et al. RETRACTED: Use of biologics in patients with psoriasis – A retrospective analysis based on real‐world data. Skin Research and Technology. 2024;30(1). doi:10.1111/srt.13550
BibTeX
@article{Pan2024,
author = {Pan, Jing and Chang, Xiaodan and Wang, Lingyan and Miao, Gang and Jin, Qiuzi and Guo, Ningning and Zhang, Jiayu and Lv, Yanwei and Wang, Lifang},
title = {RETRACTED: Use of biologics in patients with psoriasis – A retrospective analysis based on real‐world data},
journal = {Skin Research and Technology},
year = {2024},
volume = {30},
number = {1},
doi = {10.1111/srt.13550}
}
EUVIMED